An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis

Amphotericin B (AmpB) is active against leishmaniasis, but its use is hampered due to its high toxicity observed in patients. In this study, a nanoparticles-delivery system for AmpB (NQC-AmpB), containing chitosan and chondroitin sulfate molecules, was evaluated in BALB/c mice against Leishmania ama...

ver descrição completa

Detalhes bibliográficos
Autores: Ribeiro, Tatiana G., Franca, Juçara R., Fuscaldi, Leonardo L., Santos, Mara L., Duarte, Mariana C., Lage, Paula S., Martins, Vivian T., Costa, Lourena E., Fernandes, Simone O.A., Cardoso, Valbert N., Castilho, Rachel O., Soto Álvarez, Manuel, Tavares, Carlos A.P., Faraco, André A.G., Coelho, Eduardo A.F., Chávez-Fumagalli, Miguel A.
Tipo de documento: artigo
Data de publicação:2014
País:España
Recursos:Universidad Autónoma de Madrid
Repositório:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglês
OAI Identifier:oai:repositorio.uam.es:10486/690881
Acesso em linha:http://hdl.handle.net/10486/690881
https://dx.doi.org/10.2147/IJN.S68966
Access Level:Acceso aberto
Palavra-chave:Chitosan
Chondroitin sulfate
In vivo treatment
Leishmania amazonensis
Nanoparticles
Biología y Biomedicina / Biología
Descrição
Resumo:Amphotericin B (AmpB) is active against leishmaniasis, but its use is hampered due to its high toxicity observed in patients. In this study, a nanoparticles-delivery system for AmpB (NQC-AmpB), containing chitosan and chondroitin sulfate molecules, was evaluated in BALB/c mice against Leishmania amazonensis. An in vivo biodistribution study, including biochemical and toxicological evaluations, was performed to evaluate the toxicity of AmpB. Nanoparticles were radiolabeled with technetium-99m and injected in mice. The products presented a similar biodistribution in the liver, spleen, and kidneys of the animals. Free AmpB induced alterations in the body weight of the mice, which, in the biochemical analysis, indicated hepatic and renal injury, as well as morphological damage to the kidneys of the animals. In general, no significant organic alteration was observed in the animals treated with NQC-AmpB. Mice were infected with L. amazonensis and treated with the nanoparticles or free AmpB; then, parasitological and immunological analyses were performed. The NQC-AmpB group, as compared to the control groups, presented significant reductions in the lesion size and in the parasite burden in all evaluated organs. These animals presented significantly higher levels of IFN-γ and IL-12, and low levels of IL-4 and IL-10, when compared to the control groups. The NQC-AmpB system was effective in reducing the infection in the animals, and proved to be effective in diminishing the toxicity evoked by AmpB, which was observed when it was administered alone. In conclusion, NQC-AmpB could be considered a viable possibility for future studies in the treatment of leishmaniasis